Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Ribociclib plus letrozole in male patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: subgroup analysis of the phase IIIb CompLEEment-1 trial

M. Campone, M. De Laurentiis, C. Zamagni, I. Kudryavcev, M. Agterof, U. Brown-Glaberman, M. Palácová, S. Chatterjee, L. Menon-Singh, J. Wu, M. Martín

. 2022 ; 193 (1) : 95-103. [pub] 20220225

Jazyk angličtina Země Nizozemsko

Typ dokumentu klinické zkoušky, fáze III, časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc22018526
E-zdroje Online Plný text

NLK ProQuest Central od 1997-01-01 do Před 1 rokem
Medline Complete (EBSCOhost) od 2005-01-01 do Před 1 rokem
Health & Medicine (ProQuest) od 1997-01-01 do Před 1 rokem

Odkazy

PubMed 35212906
DOI 10.1007/s10549-022-06543-1
Knihovny.cz E-zdroje

PURPOSE: CompLEEment-1 (NCT02941926) is a single-arm, open-label, multicentre phase IIIb study investigating the safety and efficacy of ribociclib plus letrozole (RIB + LET) in a large, diverse cohort who have not received prior endocrine therapy (ET) for advanced disease. We present an exploratory analysis of male patients. METHODS: Eligible patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC), who had no prior ET and ≤ 1 line of prior chemotherapy for advanced disease, received RIB + LET. Male patients also received goserelin or leuprolide. Primary endpoint was safety and tolerability; efficacy was a secondary endpoint. RESULTS: In total, 39/3246 patients were male. Baseline characteristics were similar to the overall population. Male patients experienced fewer treatment-related adverse events (AEs) and treatment-related serious AEs compared with the overall population; fewer male patients had treatment-related AEs leading to discontinuation, adjustment/interruption, or additional therapy. One male patient died as a result of a serious AE that was not considered to be treatment-related. The most common AE was neutropenia; the incidence of grade ≥ 3 neutropenia in males (41.0%) was lower than in the overall population (57.2%). Median follow-up was 25.4 months; median time to progression was not reached in males versus 27.1 months for the overall population. CONCLUSION: The clinical benefit and overall response rates in males were consistent with the overall population. This analysis demonstrates the safety and efficacy of ribociclib in a close-to-real-world setting, supporting the use of RIB + LET in male patients with HR+, HER2- ABC. TRIAL REGISTRATION NUMBER: NCT02941926 (Registered 2016).

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22018526
003      
CZ-PrNML
005      
20220804134831.0
007      
ta
008      
220720s2022 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s10549-022-06543-1 $2 doi
035    __
$a (PubMed)35212906
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Campone, Mario $u Western Cancer Institute, Nantes, France. mario.campone@ico.unicancer.fr $1 https://orcid.org/0000000251965908
245    10
$a Ribociclib plus letrozole in male patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: subgroup analysis of the phase IIIb CompLEEment-1 trial / $c M. Campone, M. De Laurentiis, C. Zamagni, I. Kudryavcev, M. Agterof, U. Brown-Glaberman, M. Palácová, S. Chatterjee, L. Menon-Singh, J. Wu, M. Martín
520    9_
$a PURPOSE: CompLEEment-1 (NCT02941926) is a single-arm, open-label, multicentre phase IIIb study investigating the safety and efficacy of ribociclib plus letrozole (RIB + LET) in a large, diverse cohort who have not received prior endocrine therapy (ET) for advanced disease. We present an exploratory analysis of male patients. METHODS: Eligible patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC), who had no prior ET and ≤ 1 line of prior chemotherapy for advanced disease, received RIB + LET. Male patients also received goserelin or leuprolide. Primary endpoint was safety and tolerability; efficacy was a secondary endpoint. RESULTS: In total, 39/3246 patients were male. Baseline characteristics were similar to the overall population. Male patients experienced fewer treatment-related adverse events (AEs) and treatment-related serious AEs compared with the overall population; fewer male patients had treatment-related AEs leading to discontinuation, adjustment/interruption, or additional therapy. One male patient died as a result of a serious AE that was not considered to be treatment-related. The most common AE was neutropenia; the incidence of grade ≥ 3 neutropenia in males (41.0%) was lower than in the overall population (57.2%). Median follow-up was 25.4 months; median time to progression was not reached in males versus 27.1 months for the overall population. CONCLUSION: The clinical benefit and overall response rates in males were consistent with the overall population. This analysis demonstrates the safety and efficacy of ribociclib in a close-to-real-world setting, supporting the use of RIB + LET in male patients with HR+, HER2- ABC. TRIAL REGISTRATION NUMBER: NCT02941926 (Registered 2016).
650    _2
$a aminopyridiny $7 D000631
650    12
$a protokoly protinádorové kombinované chemoterapie $x škodlivé účinky $7 D000971
650    12
$a nádory prsu u mužů $x farmakoterapie $7 D018567
650    _2
$a lidé $7 D006801
650    _2
$a letrozol $x terapeutické užití $7 D000077289
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a neutropenie $x farmakoterapie $x etiologie $7 D009503
650    _2
$a puriny $7 D011687
650    _2
$a receptor erbB-2 $x genetika $x metabolismus $7 D018719
650    _2
$a receptory pro estrogeny $x metabolismus $7 D011960
650    _2
$a receptory progesteronu $x metabolismus $7 D011980
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a De Laurentiis, Michelino $u Istituto Nazionale Tumori IRCCS "Fondazione Pascale", Naples, Italy
700    1_
$a Zamagni, Claudio $u IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy
700    1_
$a Kudryavcev, Igor $u Kaluga Regional Clinical Oncology Center, Kaluga, Russian Federation
700    1_
$a Agterof, Mariëtte $u St. Antonius Hospital, Utrecht/Nieuwegein, The Netherlands
700    1_
$a Brown-Glaberman, Ursa $u University of New Mexico Cancer Center, Albuquerque, NM, USA
700    1_
$a Palácová, Markéta $u Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Chatterjee, Sanjoy $u Tata Medical Center, Kolkata, India
700    1_
$a Menon-Singh, Lakshmi $u Novartis Pharmaceuticals, East Hanover, NJ, USA
700    1_
$a Wu, Jiwen $u Novartis Pharmaceuticals, East Hanover, NJ, USA
700    1_
$a Martín, Miguel $u Gregorio Marañón General University Hospital, Madrid, Spain
773    0_
$w MED00009361 $t Breast cancer research and treatment $x 1573-7217 $g Roč. 193, č. 1 (2022), s. 95-103
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35212906 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804134825 $b ABA008
999    __
$a ok $b bmc $g 1822222 $s 1169769
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 193 $c 1 $d 95-103 $e 20220225 $i 1573-7217 $m Breast cancer research and treatment $n Breast Cancer Res Treat $x MED00009361
LZP    __
$a Pubmed-20220720
Zpět

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace